Intraneuronal Paired Helical Filaments Research Articles

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease

Alzheimer disease (AD) is a degenerative tauopathy characterized by aggregation of Tau protein through the repeat domain to form intraneuronal paired helical filaments (PHFs). We report two cell models in which we control the inherent toxicity of the core Tau fragment. These models demonstrate the properties of prion-like recruitment of full-length Tau into an aggregation pathway in which template-directed, endogenous truncation propagates aggregation through the core Tau binding domain. We use these in combination with dissolution of native PHFs to quantify the activity of Tau aggregation inhibitors (TAIs). We report the synthesis of novel stable crystalline leucomethylthioninium salts (LMTX®), which overcome the pharmacokinetic limitations of methylthioninium chloride. LMTX®, as either a dihydromesylate or a dihydrobromide salt, retains TAI activity in vitro and disrupts PHFs isolated from AD brain tissues at 0.16 μM. The Ki value for intracellular TAI activity, which we have been able to determine for the first time, is 0.12 μM. These values are close to the steady state trough brain concentration of methylthioninium ion (0.18 μM) that is required to arrest progression of AD on clinical and imaging end points and the minimum brain concentration (0.13 μM) required to reverse behavioral deficits and pathology in Tau transgenic mice.

Tau Pathology Generated by Overexpression of Tau

Neurofibrillary changes of abnormally hyperphosphorylated tau are the key lesion in Alzheimer’s disease (AD) and a number of other tauopathies. Recent developments in the field of autosomal dominantly inherited dementias, in particular the frontotemporal dementias and Parkinsonism linked to chromosome 17 (FTDP-17) group, have shown that abnormalities in the tau gene result in neurofibrillary degeneration and cell death. Clinically this disorder presents with behavioral abnormalities, which are followed by dementia and, depending on the affected areas, by motor dysfunction. The location of the lesions does not seem to depend so much on the type of mutation as on the individual’s genetic background and may vary even in the same family with the identical mutation. For instance, in one family with a P 301 S mutation in exon 10 of tau, the father presented with frontotemporal dementia, whereas the son had corticobasal degeneration. 1 FTDP-17 is associated with both exonic and intronic mutations of the tau gene. The microtubule-associated protein (MAP) tau is a family of six proteins derived by alternative mRNA splicing 2,3 from a single gene located on chromosome 17. These molecular isoforms of tau differ in whether they contain three or four tubulin binding domains/repeats of 31 or 32 amino acids each near the C-terminal end and no, one, or two inserts of 29 amino acids each at the N-terminal end of the molecule. There are nine missense mutations on tau exons 9 to 13; all but three are on exon 10. 4-7 Exon 10 codes for the additional insert of the three 4-repeat tau isoforms. The resulting mutated taus possess an altered conformation 8 and a somewhat reduced ability to bind to and assemble microtubules. 9,10 In addition to the exonic mutations, mutations at several sites have been found in the predicted stem loop structure in the 5′ splice site to exon 10. These intronic mutations and certain mutations in exon 10 that are close to the stem loop, and thus able to disrupt it, lead to two- to sixfold higher proportion of tau mRNA containing exon 10 than in control brains. 5 The tau protein resulting from intronic mutations is normal, but the ratio of 4-repeat to 3-repeat isoforms is increased. Presently it is believed that due to the increased proportion of 4-repeat tau in the case of intronic mutations and the compromised biological activity of the tau with missense mutations, excess tau is not bound to the microtubules, which can then be hyperphosphorylated and would lead to neurofibrillary degeneration. In contrast to the FTDP-17 group of diseases, no mutations in the tau gene have been reported in AD at the time of writing this Commentary. In more than 90% of the AD patients the disease occurs sporadically above 60 years of age. In less than 5% of the cases the disease segregates with mutations in the amyloid precursor protein (APP), presenilin-1 (PS-1), or presenilin-2 (PS-2) genes. 11 Frameshift mutations of APP and ubiquitin at the level of transcription have been reported to be associated with sporadic and familial AD and Down’s syndrome. 12 The occurrence of the apolipoprotein E4 allele 13 and, most recently, mutations in the β2 macroglobulin gene 14 have been reported to be risk factors for the development of the late onset, sporadic AD. AD has two prominent neuropathological lesions, the extracellular deposits of the amyloid β peptide (Aβ) as plaques and the intraneuronal paired helical filaments (PHF) of abnormally hyperphosphorylated tau, which accumulate in the neuronal cell body as neurofibrillary tangles, in the neuropil (the so-called neuropil threads), 15 and in the dystrophic neurites surrounding the neuritic plaques. The direct relationship, if any, between the tangles and β-amyloid is not yet understood. At the one extreme, in the normal aged brain there is the significant β-amyloid accumulation and minimal neurofibrillary degeneration, whereas in the early onset familial AD with mutations in the β-APP or presenilin gene, massive β-amyloid deposits, tau hyperphosphorylation, and tangle formation are always seen. The other extreme situation is represented by extensive neurofibrillary degeneration and minimal β-amyloidosis. These include tauopathies like the tangle-predominant form of senile dementia (tangle-only dementia), Guam Parkinsonism dementia complex, dementia with argyrophilic grains, Nieman Pick’s disease type C, subacute sclerosing panencephalitis, Pick’s disease, and the dementia group with mutations in the tau gene. 16 Although at present the exact role of PHF and β-amyloid in the pathogenesis of AD is not established, there is growing evidence from a number of laboratories that the intellectual deterioration in AD patients is associated with neurofibrillary degeneration. 17-20 A third and well characterized phenomenon is synaptic loss and cell death exceeding 50% in certain areas of the brain. 21,22

A βPP Peptide Carboxyl-Terminal to Aβ Is Neurotoxic

Extracellular Abeta-amyloid and intraneuronal paired helical filaments (PHFs) composed of tau protein are the neuropathological hallmark of Alzheimer's disease. Abeta is a 39- to 43-residue peptide derived by cleavage of a 695- to 770-amino-acid membrane-associate glycoprotein (termed beta-protein precursor, betaPP). Following the observation that an antiserum to an epitope located between residues 713 and 723 of betaPP770 (ie, the transmembrane region of the betaPP distal to Abeta) labels PHFs and that a synthetic peptide homologous to residues 713 to 730 of betaPP770 (betaPP713-730) is highly fibrillogenic and interacts with tau in vitro, it has been hypothesized that betaPP fragments other than Abeta may feature in the pathogenesis of Alzheimer's disease concurring with neuronal degeneration. To investigate this issue, we have analyzed the effects of the exposure of primary neuronal cultures to the synthetic peptide betaPP713-730. Cultures were prepared from rat hippocampus on embryonic day 17 and incubated with the peptide at 2.5 to 30 micromol/L concentration for 1 to 4 days. Cell viability was compared with that of control cultures exposed to a scrambled sequence of the peptide. A 4-day exposure to 20 micromol/L betaPP713-730 resulted in almost complete neuronal loss, whereas no changes were observed with the scrambled peptide. Degenerating neurons showed DNA fragmentation by agarose gel electrophoresis and apoptotic changes by light and electron microscopy. These findings support the view that betaPP sequences other than Abeta may play a role in nerve cell degeneration in Alzheimer's disease.

Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of β-amyloid protein precursor

A synthetic peptide whose sequence corresponds to the 20 carboxy-terminal amino acids of β-amyloid protein precursor (APP) was found to form fibrils in vitro. These fibrils showed birefringence in polarized light when stained with Congo red, fluoresced when bound with thioflavin S, were resistant to proteases, and had a crossβ conformation. By contrast, peptides with other sequences from the intracellular domain of APP and a peptide corresponding to this entire domain did not exhibit the full range of β-amyloid properties. These results suggest that a fragment from the C-terminus of the β-amyloid protein precursor could bind to intraneuronal paired helical filaments and account for some of its amyloid-like properties.

The Deposition of Amyloid Proteins in the Aging Mammalian Brain: Implications for Alzheimer's Disease

Dysfunction and loss of neurons and their processes in Alzheimer's disease is accompanied by the progressive accumulation of intraneuronal and extracellular proteinaceous filaments. Currently available evidence indicates that the principal confirmed constituent of the intraneuronal paired helical filaments (PHF) is the microtubule-associated protein, tau. Whether other neuronal proteins contribute to the PHF remains unresolved. The amyloid filaments found in cerebral and meningeal microvessels and in the centers of senile plaques appear so far to be protein chemically and immunochemically distinct from the intraneuronal PHF. The native precursor of the beta-amyloid protein comprising these amyloid filaments has now been identified and characterized in brain, non-neural tissues and cDNA-transfected cells of several species, including humans. It occurs as a heterogeneous group of approximately 105-135 kD membrane-associated proteins. cDNA-transfected cells reproduce certain beta-amyloid precursor fragment patterns observed in human brain tissue, including a favored and stable 11 kd fragment containing the carboxyl terminus and presumably the beta-amyloid region. Circulating forms of the precursor have been specifically detected in human cerebrospinal fluid. Understanding the processing of the beta-amyloid precursor protein and the origin of beta-amyloid deposits should provide insights into a potentially seminal feature of cortical degeneration in Alzheimer's disease.

X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation

X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation

X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation.

Information about the structure of the paired helical filaments (PHF) that accumulate within human neurons and the amyloid fibers that accumulate in the extracellular spaces between neurons in Alzheimer disease has so far depended on electron microscopy of thin-sectioned or negatively stained material. To determine the protein conformation of these abnormal fibers, we have obtained x-ray diffraction patterns from unfixed human brain fractions highly enriched in PHF and from purified amyloid cores isolated from senile plaques. The predominant x-ray scatter evident from both types of samples, either wet or dry, is a sharp reflection at 4.76-A spacing and a diffuse one at about 10.6-A spacing. These features are characteristic of a beta-pleated sheet type of protein conformation. In doubly oriented dried pellets of PHF fractions, the two reflections are accentuated at right angles to each other and the arc at 4.76-A spacing is in the fiber direction indicating a cross-beta conformation. From the integral widths of the reflections we estimate the cross-beta crystallite to be about 80 A long in the fiber direction and about 40 A thick. These dimensions correspond to approximately four pleated sheets, each of which consists of approximately 16 hydrogen-bonded polypeptide chains running normal to the fiber direction. The cross-beta conformation of PHF and amyloid fibers that we have found from x-ray diffraction is in contrast to the predominant alpha-helical coiled-coil conformation of the neurofilaments with which they share epitopes and from which they have been postulated to derive.